Three Generations of Cyclosporine A Formulations: An In Vitro Comparison

References

• Amante, A. J., Mier-Kriesche, H. U., Schoenberg, L., & Kahan, B. D. (2001). A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation. Transplant International, 10, 217–222.
   Google Scholar
• Barone, G., Bunke, C. M., Choc, M. G. J., Hricik, D. E., Jin, J. H., Klein, J. B., Marsh, C. L., Min, D. I., Pescovitz, M. D., & Pollak, E. (2001). The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group. Transplantation, 61, 968–970., [CSA]
   Google Scholar
• Faulds, D., Goa, K. L., & Benfield, P. (1993). Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, 45, 953–1040., [PUBMED], [INFOTRIEVE]
   Google Scholar
• Frei, U. A., Neumayer, H. H., Buchholz, B., Niese, D. & Mueller, E. A. (1998). Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. Transplantation, 65, 1455–1460., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Gaspari, F., Perico, N., Pisoni, R., Anedda, M. F., Signorini, O., Caruso, R., Gotti, E., & Remuzzi, G. (1998). How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?. Clinical Transplantation, 12, 379–390., [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Gupta, S. K., & Benet, L. Z. (1990). High-fat meals increase the clearance of cyclosporine. Pharmaceutical Research, 7, 46–48., [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Hässner, K. (2004). Rote Liste 2004. Aulendorf, Germany: Editio Cantor Verlag.
   Google Scholar
• Haug, M., III, & Wimberley, S. L. (2000). Problems with the automatic switching of generic cyclosporine oral solution for the innovator product. American Journal of Health-System Pharmacy, 57, 1349–1353., [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Holt, D. W., Mueller, E. A., Kovarik, J. M., van Bree, J. B., & Kutz, K. (1994). The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplantation Proceedings, 26, 2935–2939., [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Humberstone, A. J., & Charman, W. N. (2001). Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Advanced Drug Delivery Reviews, 25, 103–128., [CSA], [CROSSREF]
   Google Scholar
• Johnston, A., & Holt, D. W. (1998). Generic substitution for cyclosporine: what should we be looking for in new formulations? Transplantation Proceedings, 30, 1652–1653., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Johnston, A., & Holt, D. W. (2001). Bioequivalence criteria for cyclosporine. Transplantation Proceedings, 31, 1649–1653., [CSA], [CROSSREF]
   Google Scholar
• Johnston, A., Keown, P. A., & Holt, D. W. (1997). Simple bioequivalence criteria: Are they relevant to critical dose drugs? Experience gained from cyclosporine. Therapeutic Drug Monitoring, 19, 375–381., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Johnston, A., Belitsky, P., Frei, U., Horvath, J., Hoyer, P., Helderman, J. H., Oellerich, M., Pollard, S., Riad, H., Rigotti, P., Keown, P., & Nashan, B. (2004). Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. European Journal of Clinical Pharmacology, 60, 389–395., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Kahan, B. D. (1999). Recommendations concerning the introduction of generic formulations of cyclosporine. Transplantation Proceedings, 31, 1634–1684., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Kahan, B. D., Welsh, M., Schoenberg, L., Rutzky, L. P., Katz, S. M., Ubauer, D. L., & Van Buren, C. T. (1996). Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation, 62, 599–606., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Kovarik, J. M., Mueller, E. A., van Bree, J. B., Arns, W., Renner, E., & Kutz, K. (1993). Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Therapeutic Drug Monitoring, 16, 232–237.
   Google Scholar
• Kovarik, J. M., Mueller, E. A., van Bree, J. B., Tetzloff, W., & Kutz, K. (1994). Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. Journal of Pharmaceutical Sciences, 83, 444–446., [PUBMED], [INFOTRIEVE]
   Google Scholar
• Kovarik, J. M., Mueller, E. A., Richard, F., Niese, D., Halloran, P. F., Jeffrey, J., Paul, L. C., & Keown, P. A. (2001). Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation, 62, 759–763., [CSA]
   Google Scholar
• Lemaire, M., Fahr, A., & Maurer, G. (1990). Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways. Transplantation Proceedings, 22, 1110–1112., [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Mueller, E. A. (1994). Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharmaceutical Research, 11, 301–304., [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Muller, R. H., & Hildebrand, G. (1998). Perorale mikroemulsionen. In: Pharmazeutische Technologie: Moderne Arzneiformen (2nd Ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft GmBH, 169–177.
   Google Scholar
• Mueller, E. A., Kovarik, J. M., & Kutz, K. (1994a). Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. Transplantation Proceedings, 26, 2957–2958., [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Mueller, E. A., Kovarik, J. M., van Bree, J. B., Grevel, J., Luecker, P. W., & Kutz, K. (1994b). Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharmaceutical Research, 11, 151–155., [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Neumayer, H.-H. (1996). Cyclosporin as microemulsion—is it a new, drug? Nephrology Dialysis Transplantation, 11, 19–20., [CSA]
   Google Scholar
• Neumayer, H. H., Farber, L., Haller, P., Kohnen, R., Maibucher, A., Schuster, A., Vollmar, J., & Waiser, J. (1994). Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after 1 month. Transplantation Proceedings, 26, 2944–2948., [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Olyaei, A. J., deMattos, A. M., & Bennett, W. M. (1997). Switching between cyclosporin formulations. What are the risks? Drugs and Aging, 16, 366–373.
   Google Scholar
• Penaud, J. F., Decroix, M. O., Arnaud, P., Magne, D., Gobert, J. G., & Chaumeil, J. C. (1996). In vitro study of cyclosporin absorption: vehicles and intestinal immaturity. International Journal of Pharmaceutics, 142, 1–8., [CROSSREF]
   Google Scholar
• Pfüller, U. (1985). Mizellen-Vesikel-Mikroemulsionen, Tensidassoziate and ihre Anwendung in Analytik und Biochemie. Berlin: Springer-Verlag.
   Google Scholar
• Pollard, S., Nashan, B., Johnston, A., Hoyer, P., Belitsky, P., Keown, P., & Helderman, H. (2003). A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clinical Therapeutics, 25(6), 1654–1669., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Ritschel, W. A. (2001). Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clinical Transplantation, 10, 364–373., [CSA]
   Google Scholar
• Senel, F. M., Yildirim, S., Karakayali, H., Moray, G., & Haberal, M. (1997). Comparison of Neoral and Sandimmun for induction and maintenance immunosuppression after kidney transplantation. Transplant International, 10, 357–361., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Shah, M. B., Martin, J. E., Schroeder, T. J., & First, M. R. (1998). A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Transplantation Proceedings, 30, 4048–4053., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Tan, K. K. C., Trull, A. K., Uttridge, J. A., Metcalfe, S., Heyes, C. S., Facey, S., & Evans, D. B. (1995). Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients. Clinical Pharmacology and Therapeutics (St. Louis), 57, 425–433., [CSA], [CROSSREF]
   Google Scholar
• Tarr, B. D., & Yalkowsky, S. H. (1989). Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharmaceutical Research, 6, 40–43., [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Washington, C. (1992). Photon correlation spectroscopy. In: Particle Size Analysis in Pharmaceutics and Other Industries—Theory and Practice. ChichesterUK: Ellis Horwood Limited, 135–155.
   Google Scholar